Grifols has acquired its existing portfolio company Alkahest, five years after buying a 45% stake in the Stanford University spinout.

Alkahest, a US-based neurodegenerative disease drug developer spun out of Stanford University, agreed to an acquisition by pharmaceutical firm Grifols for $146m yesterday. The transaction is subject to regulatory approval and is expected to close early next year. Founded in 2014, Alkahest is working on therapies based on the company’s map of the human plasma…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.